Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has been featured in a BioMedWire editorial that examines the expanding market opportunity for next-generation DNA Damage Response (DDR) inhibitors. The editorial, titled "Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market," underscores the continued growth of DDR-targeted therapies as the global oncology, diagnostics, and precision medicine markets evolve.
The piece highlights Onco-Innovations' lead candidate, ONC010, a nanoparticle-encapsulated PNKP inhibitor that targets a DNA repair enzyme involved in multiple repair pathways. According to the company, this clinical-stage therapy is positioned as a next-generation synthetic lethality candidate within the biopharmaceutical and biotechnology landscape.
The editorial discusses how DDR inhibitors, particularly PARP inhibitors, have already shown success in treating cancers with BRCA mutations, but next-generation inhibitors like ONC010 aim to expand the reach of synthetic lethality to a broader range of tumors. PNKP plays a critical role in repairing DNA single-strand breaks, and its inhibition could enhance the effectiveness of radiation and chemotherapy.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumors.
For more details, the full press release is available at https://ibn.fm/yCAwZ. The latest news and updates related to ONNVF can be found in the company's newsroom at https://ibn.fm/ONNVF.
